Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.88 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.75 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408209 | 1.00 | DGAT1 (0.88) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL10198073 | 1.00 | DGAT1 (0.88) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL406049 | 0.95 | DGAT1 (0.94) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL406050 | 0.95 | DGAT1 (0.94) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL10198074 | 0.95 | DGAT1 (0.94) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL409879 | 0.94 | DGAT1 (0.98) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL409878 | 0.94 | DGAT1 (0.98) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL10198078 | 0.94 | DGAT1 (0.98) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL406759 | 0.94 | DGAT1 (1.00) | DGAT1SOAT2SOAT1ALDH1A1TP53 | |
| SCHEMBL406758 | 0.94 | DGAT1 (1.00) | DGAT1SOAT2SOAT1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT2 9/4885SOAT1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.